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tumours failed to respond because prolactin
was not abolished; (5) 2/2 oestrogen depen-
dent tumours got worse on oestrogens; (6)
2/2androgen dependent tumours gotworseon
testosterone; (7) 10/11 in vitro independent
tumours failed to respond. The in vitro test
thus gave a correct prediction in 37 of 40
patients.
CHANGES IN RESPONSE TO
CHEMOTHERAPEUTIC AGENTS
DURING THE LIFE HISTORY OF
MONOLAYER CULTURES OF A
MOUSE TUMOUR CELL LINE. P. R.
TWENTYMAN andN. M. BLEEHEN. Academic
Department of Radiotherapy, Middlesex
Hospital Medical School, London.
At the previous meeting of the Associa-
tion, we described how EMT6 mouse tumour
cells become less sensitive to bleomycin as
they pass from exponential growth into
plateau phase. This result was the opposite
of that reported by other workers using
Chinese hamster cells. Detailed investigation
of the proliferation kinetics of our EMT6 cell
line has revealed that the plateau phase may
be subdivided into early plateau (with a pulse
labelling index of 25% and considerable cell
loss) and late plateau (with a labelling index
of <5% and little cell loss). Sensitivity to
bleomycin is indeed reduced during early
plateau (compared with exponentially grow-
ing cells), but in late plateau the sensitivity
becomes greater than that in exponential
cells. Sensitivity to a number of other
chemotherapeutic agents has also been in-
vestigated in cultures of various ages.
THE EFFECT OF WHOLE BODY
HYPERTHERMIA IN ADVANCED
CANCER. R. T. PETTIGREW, C. M.
LUDGATE and A. N. SMITH. Department of
Anaesthetics and Department of Clinical
Surgery, Western General Hospital and
University of Edinburgh.
The anaesthetized patient is immersed in
molten wax at 50°C. This reverses the
normal physiological processes of heat loss.
A 5°C rise is achieved in one hour and main-
tained for 3-4 h. Fifty-five patients with
advanced cancer have been heated to 41F80C
and the tumour response assessed by criteria
which include relief of pain, weight gain,
serial biopsy changes and evidence oftumour
regression. One group (45 patients) was
treated by hyperthermia alone; sarcomata
and gastrointestinal tract tumours were the
most responsive (8 in 11); an intermediate
group, skin and lung tumours, was less so
(6 in 16); a third (mainly genito-urinary),
the least (0 in 14). The addition of chemo-
therapy to hypertherrnia in 10 patients
raised the proportion regressing from 11 in 23
(48%) to 7 in 10 (70%). Occasional com-
plications were mild superficial burns, tra-
cheitis, ventricular fibrillation and dissemi-
nated intravascular coagulation.
ANALYSIS OF THE ANTIMETA-
STATIC ACTION OF THE ANTIMI-
TOTIC AGENT ICRF 159. K. HELLMANN,
S. E. JAMES and A. J. SALSBURY. Imperial
Cancer Research Fund, London.
ICRF 159 inhibits metastases from the
spontaneously metastasizing Lewis lung car-
cinoma (3LL) without markedly impeding
the growth of the primary implant. It has
previously been proposed that this anti-
metastic action of ICRF 159 is due to the
inhibition of malignant cell release from the
primary tumour consequent upon normaliza-
tion ofthe tumour blood vessels by the drug.
Lung " metastases " due to intravenous
injection of 3LL cells should theiefore be un-
affected by ICRF 159 administration. This
was not, however, found to be the case.
When primary tumours were excised up
to 6 days following implantation, secondary
growths were not apparent in the lungs at 21
days. Treatment ofprimary tumours for the
first 6 days by 30 mg/kg ICRF 159, at a time
therefore when no circulating malignant cells
would have been present, produced an almost
complete inhibition of metastases. Thus,
under these conditions the antimetastatic
action cannot be ascribed to an effect of the
drug on 3LL cells in the blood stream.
A COMPARISON OF THE CELL
KILLING IN THE MOUSE AFTER
EXPOSURE TO FTORAFUR AND TO
5-FLUOROURACIL. L. M. VAN PUTTEN,
L. K. J. KRAM-IDSENGA and M. PIJPERS-DE
BRUIN. Radiobiological Institute TNO, Rijs-
wijk, Holland.
Ftorafur (N-i-(furanidyl)-5 fluorouracil)
was compared with 5-fluorouracil (5-FU) in
mice. The LD5o and the slopes of the dose-
effect curves for killing of L1210 leukaemia180 B.A.C.R. 15TH ANNUAL GENERAL MEETING
cells and of haemopoietic stem cells in the
bone marrow indicate that Ftorafur is 2-3
times less effective than 5-FU. However, it
is about 7 times less effective in killing
rapidly proliferating haemopoietic stem cells.
This finding is hard to explain since Ftorafur
is reported to be active only through release
of 5-FU, a report which is in agreement with
our observation of ineffectiveness of Ftorafur
upon incubation in vitro in concentrations 10
times higher than effective 5-FU concentra-
tions. On the other hand, the lower toxicity
of Ftorafur for proliferating stem cells might
explain the reported better tolerance upon
prolonged administration to patients in
comparison with equally effective doses of
5-FU. A study, made to verify this, has
indicated that upon fractionated administra-
tion Ftorafur is not only much less toxic than
5-FU but also less effective in killing L 1210
cells.
If conditions in man are comparable with
those in mice, part of the good haemato-
logical tolerance to prolonged administration
of Ftorafur may be due to a decrease in the
fraction of the drug being hydrolyzed to
liberate 5-FU.
RECENT RESULTS WITH CARCINO-
GEN BINDING PROTEINS. B.
KETTERER and E. TIPPING. Middlesex
Hospital Medical School. D. BEALE. ARC
Institute ofAnimalPhysiology. B. ABRAHAM
and J. MEUWISSEN. Katholieke Universiteit
te Leuven, Belgium.
Three azodye carcinogen binding proteins
have been purified in our laboratories with
sedimentation coefficients of 4 7, 3-5 and
1 7S. The 4 7S protein has a pl of 9 0, a low
tyrosine and a high CyS content, a complex
absorption spectrum for bound azodye and
readily dissociates into subunits.
The 3 5S protein, ligandin, is a relatively
small molecule composed of two apparently
identical subunits of MW 23,000. It never-
theless binds ligands as diverse as oestrone
sulphate, bilirubin and haematin with affinity
constants for the first binding site of 106 to
at least 108.
The abundance and wide tissue distribu-
tion ofligandin make it ofparticular interest.
An apparent connection with drug meta-
bolizing enzymes indicates that it is more
than an intracellular equivalent of serum
albumin.
LACK OF SYNERGY BETWEEN N-
METHYL-N-NITROSOUREA (MNU)
AND CYCLOPHOSPHAMIDE (CP) IN
RAT URINARY BLADDER. J. ST. J.
WAKEFIELD and R. M. HICKS. Middlesex
Hospital Medical School, London.
A single, intravesicular dose of MNU is
non-carcinogenic in the normal life span ofthe
rat. By contrast, 4 bi-weekly doses produce
bladder tumours from 15 weeks on (Hicks
and Wakefield, Chem-Biol. Interact., 1972, 5,
139). Each dose is followed by necrosis then
hyperplasia of the epithelium. Intraperi-
toneal injection of CP also causes necrosis
followed by hyperplasia of the bladder epi-
thelium, but no tumours develop after
multiple (12) doses. This suggests that pro-
longed hyperplasia per se is not carcinogenic
in the absence of some further stimulus.
Rats given either a single dose of MNU
followed by CP, or CP followed by a single
dose ofMNU, also failed to develop tumours.
These results show no co-carcinogenesis with
MNU and CP, even though the target tissue
for both compounds is the same.
SYNCARCINOGENESIS WITH N-
METHYL N-NITROSOUREA (MNU)
AND CYCLAMATE IN RAT URINARY
BLADDER. J. CHOWANIEC, J. ST. J.
WAKEFIELD and R. M. HICKS. Middlesex
Hospital Medical School, London.
Cyclamate is suspect as a bladder carci-
nogen, but reports from different experi-
mentalists are conflicting. In this laboratory,
only one animal on a cyclamate containing
diet has so far developed a bladder tumour in
the absence of any other treatment.
One intravesicular dose of MNU is not
carcinogenic but 4 doses are (Hicks and
Wakefield, Chem-Biol. Interact., 1972, 5, 139).
Animals which have received one intra-
vesicular dose of MNU are now being main-
tained on a cyclamate containing diet. Of
these, 21 animals have been killed so far and
9 had bladder tumours. These results
demonstrate syncarcinogenesis with MNU
and cyclamate in the bladder. By contrast,
co-carcinogenesis could not be demonstrated
with MNU and the cytotoxic, but not carci-
nogenic, cyclophosphamide (see previous
abstract, J. St. J. Wakefield and R. M.
Hicks). We suggest that cyclamate may be
a weak bladder carcinogen, not normally
effective in the life span of the animal.